Catalog No.: PC-38704Not For Human Use, Lab Use Only.
DF2755A is a selective, allosteric, orally acting inhibitor of CXCR1/2 (Kd=2.24/0.94 nM), inhibits human PMN (hPMN) migration induced by CXCL8 and CXCL1 with IC50 of 4.2 and 2.1 nM, respectively.
DF2755A is a selective, allosteric, orally acting inhibitor of CXCR1/2 (Kd=2.24/0.94 nM), inhibits human PMN (hPMN) migration induced by CXCL8 and CXCL1 with IC50 of 4.2 and 2.1 nM, respectively.
DF2755A is equally efficacious in inhibiting CXCL8- and CXCL1-induced hPMN chemotaxis induced by an optimal concentration of CXCL8 (1 nM) or CXCL1 (10 nM).
DF2755A selectively inhibited neutrophil chemotaxis induced by CXCR1/2 ligands without effect on CXCL8 binding to neutrophils.
DF2755A (3-30 mg/kg, p.o.) reduced inflammatory hyperalgesia induced by carrageenan, LPS and CXCL1/KC as well as neutrophil recruitment and IL-1β production in vivo.
